Clinical Trial Update: Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nab-sirolimus with endocrine therapy for recurrent low-grade serous ovarian carcinoma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Serous Ovarian Carcinoma

Drugs mentioned

• Endocrine therapy
• nab-sirolimus (sirolimus (nanoparticle albumin-bound formulation))

Snippet

Sponsor: University of Oklahoma | Conditions: Low Grade Ovarian Serous Adenocarcinoma | Phase 2 | Status: RECRUITING